Business Wire

PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme

Jaa

PharmAbcine Inc., a clinical-stage biotech company developing novel antibody therapeutics for multiple cancer indications, announced today that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its leading clinical compound TTAC-0001 for “treatment of Glioblastoma Multiforme.”

“We are very pleased with this Orphan Drug Designation from FDA for TTAC-0001 for GBM treatment since we have been preparing for clinical studies of TTAC-0001 plus KEYTRUDA® (pembrolizumab) combo therapy for recurrent GBM in addition to TTAC-0001 mono therapy for recurrent GBM progressed after bevacizumab treatment. It will accelerate the progress of TTAC-0001 to provide clinical benefit in the treatment of GBM,” said Dr. Jin-San Yoo, president and chief executive officer of PharmAbcine, Inc.

The FDA Office of Orphan Products Development grants Orphan Drug Designation to investigational drugs and biologics that are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. Orphan drug status is intended to facilitate drug development for rare diseases and may provide several benefits to drug developers, including seven years of market exclusivity upon regulatory product approval, exemptions from certain FDA application fees, and tax credits for qualified clinical trials costs.

About TTAC-0001 (=Tanibirumab)

PharmAbcine’s lead candidate TTAC-0001, an investigational therapy, is a highly selective and potent anti-VEGFR2 (KDR/flk-1) mAb in clinical development for rGBM indications. VEGFR2 is over-expressed in most malignant tumors, such as gastric, liver, non-small cell lung cancer (NSCLC), ovarian, brain, colorectal, and breast cancers and this signaling pathway is a key regulator for tumor angiogenesis.

Increased understanding of the role of VEGF/VEGFR2 in the tumor vessel formation, immune suppressive modulation of tumor microenvironment (TME) and the function of the antagonist molecule to disorganized tumor vessel normalization, immune supportive modulation, and ultimately tumor vessel disruption, supports the rationale for evaluating TTAC-0001 in GBM, rGBM and Avastin® (bevacizumab) refractory GBM.

About PharmAbcine Inc.

PharmAbcine is a leading clinical stage biologics company that develops fully human therapeutic antibody (mAb) and next generation multispecific antibody therapeutics based on in-house developed novel platform, DIG-Body, PIG-Body and TIG-Body using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.

PharmAbcine’s fully human antibody libraries and innovative selection system are our priceless proprietary assets. PharmAbcine provides antibody generation services by using antibody library and selection systems. PharmAbcine also provides co-development opportunities with novel antibodies.

Under the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has >300 patients derived cancer stem cell libraries and its animal model system for evaluating internal pipeline development.

Selected pipeline:

TTAC-0001(=Tanibirumab): anti-KDR neutralizing fully human IgG with unique cross species cross reactivity has completed its Phase IIa recurrent GBM trial in Australia in August 2017 and its final report will be available early in 2018. Promising molecule to combine with immune checkpoint blockade is open for out-licensing, co-development and combination clinical trials.

PMC-001(=DIG-KT): next generation bispecific antibody neutralizing both VEGF-KDR and Angiopoietin-TIE2 pathways is superior to bevacizumab and Tanibirumab in preliminary studies. It also overcomes the Avastin resistant brain tumor growth. PMC-002, PMC-003, PMC-004 are derivative molecules from PMC-001.

PMC-201: next generation bispecific antibody neutralizing both VEGF-KDR and Notch-DLL4 pathways overcomes anti-cancer drug resistant tumor growth.

PMC-005B: Anti-EGFRviii truly specific fully human IgG with internalization property is perfect for ADC, CAR-T and CAR-NK purpose and is open for codevelopment or out-licensing.

PMC-309a-z: anti-VISTA fully human antibodies collection as either agonistic or antagonistic. Antagonistic antibody performed synergy effects in combination with other immuno-oncology drug.

"3G-System" platform provides high performing production cell lines and we do have both

PMC-901: bevacizumab biosimilar cell line with 3g/L productivity.
PMC-902: aflibercept biosimilar cell line with >3g/L productivity.

Additional information about PharmAbcine is available through its website, https://www.pharmabcine.com

About GBM, recurrent GBM and Avastin refractory recurrent GBM

Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults, with a median survival of less than 15 months from diagnosis and recurs frequently within a year following the initial treatment. Chemotherapy, radiation and surgery are the primary initial treatments; chemotherapy and surgery may be possible for recurrent disease, with limitations in using radiation dependent on the site of recurrence. Avastin is approved as an active treatment option (single agent) for patients with rGBM who have failed previous TMZ and radiation therapy. During Avastin treatment, some of patients become Avastin refractory recurrent GBM.

Contact information

Media Contacts
For PharmAbcine:
Dr. Sung Woo Kim, 82-42-863-2017
sungwoo.kim@pharmabcine.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Board Members Serve as the Critical Link to Security and Corporate Governance, Diligent Survey Finds17.10.2018 22:48Tiedote

Board members and executives are not taking enough precautions when executing board communications, according to a new report from Diligent Corporation entitled “Directors’ Digital Divide: Boardroom Practices Aren’t Keeping Pace With Technology.” The survey found that while 87% of firms are concerned with the security of their board communications and data sharing, more than half (55%) of their board members still use personal email for board communication, exposing themselves and the boards to potential cyber-attacks. In this survey, Forrester Consulting conducted research targeting board members, general counsels and administrators from 11 countries to better understand the current global state of governance amidst rapid technological disruption. Having access to more boardrooms than any other company, Diligent is uniquely positioned to provide insight into businesses’ cyber risk, regulation and culture practice – as well as how these critical governance areas can be improved. “Techn

JPMorgan Chase Bank Announces Initial Exchange Price for the Cash-Settled Exchangeable Bonds into Dufry Due 202117.10.2018 21:13Tiedote

Following the placement on 10 October 2018, JPMorgan Chase Bank, N.A. today announces the initial exchange price of the cash-settled exchangeable bonds due 2021 (the “Bonds”) in aggregate principal amount of USD 205 million, referable to ordinary shares of Dufry AG (the “Shares”) The initial exchange price of the Bonds has been set at CHF 134.8547, representing a 25% premium over the reference share price of CHF 107.8837, which was determined in the manner described in the press announcements released on 10 October 2018 and based on a Reference FX Rate of CHF:USD 1.0096. Settlement and delivery of the Bonds took place today. About JPMorgan Chase & Co. JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $2.6 trillion and operations worldwide. The firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. A component of the Dow Jones Indu

Mouser Electronics and Grant Imahara Launch New Series All Things IoT about Technology Redefining How We Live17.10.2018 18:40Tiedote

Mouser Electronics Inc. and celebrity engineer Grant Imahara today released a new video introducing All Things IoT, the latest series in Mouser’s award-winning Empowering Innovation Together™ program. The All Things IoT series is sponsored by Mouser’s valued suppliers Digi International, Maxim Integrated, Murata and TE Connectivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005655/en/ Global distributor Mouser Electronics and engineer spokesperson Grant Imahara team up to launch All Things IoT, the latest series in Mouser's Empowering Innovation Together program. The new series kicks off with Imahara's visit to the HPE IoT Innovation Lab in Houston to learn how the Internet of Things is impacting our workplaces and cities. To learn more, visit www.mouser.com/empowering-innovation/all-things-iot. (Photo: Business Wire) In the new video, Imahara and Mouser explore the complexities of life rooted in the Internet of T

Telefónica Deutschland Selects Mavenir vIMS for Deployment on ‘UNICA’17.10.2018 17:59Tiedote

Mavenir, the leader in accelerating and redefining mobile network economics transformation for Communications Service Providers (CSPs), today announced that Telefónica Deutschland (FWB: O2D) is deploying Mavenir’s virtualized IMS solution (vIMS) for VoLTE and VoWiFi in their nationwide UNICA Data Centers Infrastructure, which is based on the Telefónica Group blueprint for Network Functions Virtualization (NFV) architecture. The solution will support mobile and fixed services for more than 45 million customer connections. The NFV environment is based on OpenStack® and will include automation, life cycle management and integration with Management and Orchestration (MANO) capabilities from the Telefónica UNICA platform. The Mavenir advanced vIMS solution will enable automation from day one and will support existing voice digital services as well as the launch of new services. As a software-based company leading the Telco NFV industry, Mavenir is a perfect match with Telefónica UNICA NFV s

Lenovo and Scale Computing Collaborate to Solve Edge Infrastructure Challenges for Retailers17.10.2018 17:34Tiedote

Lenovo (HKSE: 992) (ADR: LNVGY), a Global Fortune 500 company and a technology leader in Intelligent Transformation, and Scale Computing, a market leader in intelligent edge solutions, today announced a global partnership and a new joint product providing a solution for edge infrastructure for global retailers, distributed enterprises and small and medium-sized businesses. The solution is ideal for highly distributed, on-premise environments, such as retail stores or bank branches, with multiple locations managed by the enterprise from a central location. Lenovo’s broad range of servers combined with efficient, intelligent edge infrastructure software from Scale Computing deliver a simple, self-healing, highly-available platform for running applications at the edge or hybrid edge-and-cloud. The Scale Computing HC3 Edge Platform on Lenovo Servers replaces traditional complex and expensive on-premise infrastructure with a modern solution optimized for environments where application uptim

As Hilton Nears 100-Year Milestone, New Research Uncovers a World-Changing Impact17.10.2018 16:24Tiedote

As Hilton (NYSE: HLT) heads toward a milestone 100th anniversary in 2019, best-selling author and Stanford Business professor Chip Heath will unveil the impact the first global hotel company has had around the world in a new book titled The Hilton Effect. Business author Karla Starr joined him in the examination of the company founded by Conrad Hilton, a dreamer who aspired to create much more than just a comfortable place to sleep. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005486/en/ As Hilton nears 100-year milestone, new research uncovers a world-changing impact. (Graphic: Business Wire) Over the last century, Hilton has grown from a single hotel in Cisco, Texas, to nearly 5,500 hotels and 14 brands in 106 countries and territories. Hilton’s hotels have hosted more than 3 billion guests since 1919 and enlisted nearly 10 million Team Members in the company’s mission to fill the Earth with the light and warmth of

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme